IMA203

Moderna has partnered with Immatics to develop mRNA-based cancer vaccines, bispecifics and cell therapies. The deal includes a $120 million upfront payment and up to $1.7 billion in milestones.

Moderna expands cancer vaccine portfolio with Immatics deal worth up to $1.7B

Anika Sharma

Moderna is intensifying its focus on cancer vaccines and cell therapies through a newly announced research partnership with Immatics, a ...